TcLand Expression launches the "PRINT" international clinical trial to validate its blood biomarker RA-INF-Dx and announces the recruitment of its first patient
TcLand Expression SA announced the launch of the PRINT trial ("Predicting non-response to infliximab therapy") and the recruitment of its first patient in a French rheumatology center. PRINT is a prospective, international, multicenter trial seeking to validate the blood-based biomarker RA-INF-Dx as a predictive, multigene molecular diagnostic for identifying rheumatoid arthritis patients who are unlikely to respond to infliximab (Remicade®), a monoclonal antibody targeting tumor necrosis factor (TNF). In all, 200 patients will included in the study by around 25 investigating centers in 7 European countries.
"The RA-INF-Dx predictive blood test will constitute a major step forward in the management of rheumatoid arthritis patients. RA-INF-Dx will help to optimize treatment with infliximab by identifying non-responder patients prior to the initiation of anti-TNF therapy. This will enable clinicians to offer patients the most suitable treatment option, reduce the incidence of potential short- and long-term side effects and thus positively influence quality of care and overall healthcare costs", emphasized Patrick Larcier, Vice President of Clinical and Regulatory Affairs at TcLand Expression.
Other news from the department research and development
